AMPHASTAR PHARMACEUTICALS INC. 2024-2025 Proxy Voting Records

Description as filed by funds: To elect three Class III directors to serve until the Company's 2028 annual meeting of stockholders and until each such director's successor is elected and qualified or until such director's earlier death, resignation or removal: Diane G. Gerst

AMPHASTAR PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Diane G. Gerst”): 26,544,774 for, 10,942,687 against, per its Form 8-K filed June 4, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors Each director nominee was duly elected to serve until the 2028 annual meeting of stockholders and until his or her successor is duly elected and qualified or until such director's earlier death, resignation or removal.”
Support: 71% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 86 asset managers below reported 9,697,649 for, 5,226,026 against, 3,844 abstained.

Showing the 25 largest of 86 asset managers. See all 86 in the interactive database.

Description as filed by funds: To elect three Class III directors to serve until the Company's 2028 annual meeting of stockholders and until each such director's successor is elected and qualified or until such director's earlier death, resignation or removal: Jack Y. Zhang

AMPHASTAR PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Jack Y. Zhang”): 35,324,626 for, 2,162,135 against, per its Form 8-K filed June 4, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors Each director nominee was duly elected to serve until the 2028 annual meeting of stockholders and until his or her successor is duly elected and qualified or until such director's earlier death, resignation or removal.”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 86 asset managers below reported 14,014,153 for, 909,522 against, 3,844 abstained.

Showing the 25 largest of 86 asset managers. See all 86 in the interactive database.

Description as filed by funds: To elect three Class III directors to serve until the Company's 2028 annual meeting of stockholders and until each such director's successor is elected and qualified or until such director's earlier death, resignation or removal: Richard Prins

AMPHASTAR PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Richard Prins”): 33,537,101 for, 3,949,663 against, per its Form 8-K filed June 4, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Election of Directors Each director nominee was duly elected to serve until the 2028 annual meeting of stockholders and until his or her successor is duly elected and qualified or until such director's earlier death, resignation or removal.”
Support: 89% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 86 asset managers below reported 13,158,417 for, 1,765,258 against, 3,844 abstained.

Showing the 25 largest of 86 asset managers. See all 86 in the interactive database.

Description as filed by funds: To approve the amendment of our Amended and Restated Certificate of Incorporation to reflect Delaware law provisions regarding officer exculpation; and

AMPHASTAR PHARMACEUTICALS INC.’s own tally for this item (“4. To approve the amendment of the Charter to reflect Delaware law provisions regarding officer exculpation; and”): 34,496,144 for, 2,910,874 against — passed, per its Form 8-K filed June 4, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The stockholders approved the amendment to the Charter to reflect Delaware law provisions regarding officer exculpation.”
Support: 92% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 86 asset managers below reported 14,123,921 for, 768,254 against, 35,344 abstained.

Showing the 25 largest of 86 asset managers. See all 86 in the interactive database.

Description as filed by funds: To approve the amendment of our Amended and Restated Certificate of Incorporation to remove forum selection provision.

AMPHASTAR PHARMACEUTICALS INC.’s own tally for this item (“5. To approve the amendment of the Charter to remove forum selection provision”): 37,354,374 for, 52,330 against — passed, per its Form 8-K filed June 4, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 5: To approve the amendment of the Charter to remove forum selection provision;”
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 86 asset managers below reported 14,892,175 for, 0 against, 35,344 abstained.

Showing the 25 largest of 86 asset managers. See all 86 in the interactive database.

Description as filed by funds: To approve, on an advisory basis, the compensation of the Company's named executive officers;

AMPHASTAR PHARMACEUTICALS INC.’s own tally for this item (“3. To approve, on an advisory basis, the compensation of the Company's named executive officers”): 35,585,000 for, 1,815,521 against — passed, per its Form 8-K filed June 4, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The stockholders approved, on a non-binding basis, the compensation of the Company's named executive officers.”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 86 managers: 14,340,340 for, 551,835 against, 35,344 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 231 managers: 12,717,300 for, 1,103,874 against, 44,341 abstained, 375 not voted. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for its fiscal year ending December 31, 2025;

AMPHASTAR PHARMACEUTICALS INC.’s own tally for this item (“2. To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for its fiscal year ending December 31, 2025”): 41,473,456 for, 526,237 against — passed, per its Form 8-K filed June 4, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 87 asset managers below reported 14,921,287 for, 2,402 against, 3,844 abstained.

Showing the 25 largest of 87 asset managers. See all 87 in the interactive database.